La clozapine dans le traitement de la schizophrénie réfractaire: règles et directives canadiennes *

Lieberrnan JA , Kane JM , Johns CA . Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329–338.

Stephens P. A review of clozapine: an antipsychotic for treatment-resistant schizophrenia. Compr Psychiatry 1990; 31: 315–326.

Fitton A , Heel RC . Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drug Evaluation 1990; 40: 722–747.

Baldessarini RJ , Frankenburg F. Clozapine: a novel antypsychotic agent. N Engl J Med 1991; 323: 746–754.

CPA wants provinces to fund neuroleptic for schizophrenics who resist other drugs. The Medical Post, December 3, 1991; 27: 53.

Van Toi HH , Bunzow JR , Guan HC , Cloning of a human dopamine D₄ receptor gene with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–614.

Juul Povlsen U , Noting U , Fog R , Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71: 176–185.

Kane J , Honigfeld G , Singer J , Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.

Claghorn J , Honigfeld G , Abuzzahab FS , The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377–384.

Meltzer HY , Bastani B , Kwon KY , A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 1989; 99: S68–S72.

Meltzer HY , Burnett S , Bastani B , Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–897.

Lieberrnan JA , Yunis J , Egea E , HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47: 945–948.

Lieberrnan JA , Saltz BL , Johns CA , The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503–510.

Schatzberg AF , Cole JO . Manual of clinical psychopharmacology second edition. Washington DC: American Psychiatric Press, Inc., 1991: 98.

Revecki DA , Luce BR , Weschler JM , Cost-effectiveness of clozapine for treatment resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–854.

Honigfeld G , Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 882–885.

Perry PJ , Miller DD , Arndt SV , Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231–235.

Monographie de Clozaril. Dorval PQ: Sandoz Canada Inc., 1991.

Leadbetter R , Shutty M , Pavalonis D , Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68–72.

Anderson ES , Powers PS . Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry 1991; 52: 102–104.

Haller E , Binder RL . Clozapine and seizures. Am J Psychiatry 1990; 147: 1069–1071.

Lieberrnan JA , Johns C , Cooper T , Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 1989; 99: S54–S59.

Szymanski S , Lieberrnan JA , Picou D , A case report of Cimetidine induced clozapine toxicity. J Clin Psychiatry 1991; 52: 21–22.

Collins EJ . Enhancing the eficacy of clozapine: the integration of psychosocial treatments. In: Lapierre Y , Jones B , eds. Clozapine in treatment resistant schizophrenia. Royal Society of Medicine International Congress and Symposium Series 1992; 185: 55–58.